Tag: $GSK

GSK (GSK.L), shares fell more than 6% on Friday to the bottom of Britain’s blue-chip index after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over side effects.

Shares of AstraZeneca (ST:AZN) and GlaxoSmithKline (LON:GSK) fell on Wednesday after U.S. President Donald Trump said tariffs on imported drugs could be imposed “very soon.”

The U.S. Food and Drug Administration has approved British drugmaker GSK’s (GSK.L), asthma drug to treat some patients with a chronic lung disease commonly known as “smoker’s lung”, the company said on Thursday.

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

GSK shares jumped Wednesday on news Delaware’s top court ruled in the pharmaceutical company’s favor, by agreeing to review the admissibility of expert evidence that could play a part in the British firm’s legal fight against claims its Zantac heartburn drug causes cancer.

UK pharmaceutical group forecasts 7-9% revenue growth this year on strong performance from cancer and HIV drugs

GSK’s London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.

Shares of GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for the British drugmaker.

LONDON July 26 – GSK raised its full-year profit and sales guidance on Wednesday after its second-quarter earnings beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines.

.

U.S.-listed shares of GSK were rising in premarket trading Friday after the pharmaceutical company said it reached a first legal settlement over claims that heartburn medication Zantac can cause cancer.